Severe acute respiratory infections treatment centre: practical manual to set up and manage a SARI treatment centre and a SARI screening facility in health care facilities
Strategic communication is at the heart of public health and more important than ever in the digital age. Using communication strategically requires expertise, skills and resources to plan, implement and evaluate interventions that encourage governments to implement policies that improve people’s ...lives and well-being, that empower health workers to deliver the best care possible, and that encourage people to take actions that protect and improve their health and that of their family and community. This Regional Action Framework on Communication for Health (C4H) aims to support Member States in implementing the C4H approach. It outlines steps to be taken by WHO and Member States to use C4H to achieve shared public health goals in the Western Pacific.
more
Este documento dá orientações sobre o uso de máscaras na comunidade durante a assistência domiciliar e em serviços de saúde em regiões que têm relatado casos de COVID-19. É dirigido a indivíduos na comunidade, profissionais de saúde pública e de prevenção e controle de infecção (PCI...), administradores da saúde, profissionais de saúde e trabalhadores da saúde comunitária. O documento será revisado à medida que mais dados se tornarem disponíveis.
more
National AIDS and STI Control Program
Mund-Nasen-Bedeckung im öffentlichen Raum als weitere Komponente zur Reduktion der Übertragungen von COVID-19. Strategieergänzungen zu empfohlenen Schutzmaßnahmen und Zielen (3. Update) Das RKI empfiehlt ein generelles Tragen einer Mund-Nasen-Bedeckung (MNB) in bestimmten Situationen im öffentl...ichen Raum als einen weiteren Baustein, um Risikogruppen zu schützen und den Infektionsdruck und damit die Ausbreitungsgeschwindigkeit von COVID-19 in der Bevölkerung zu reduzieren. Diese Empfehlung beruht auf einer Neubewertung aufgrund der zunehmenden Evidenz, dass ein hoher Anteil von Übertragungen unbemerkt erfolgt, und zwar bereits vor dem Auftreten von Krankheitssymptomen. Ziel des im Epidemiologischen Bulletin 19/2020 veröffentlichten Artikels ist es, eine kurze Übersicht zum fachlichen Hintergrund der Empfehlung zu geben und zu erläutern, welche Dinge hierbei zu berücksichtigen sind.
more
Please read online the lastest updated versions http://www.cdc.gov/vhf/ebola/qa.html
Operational Guidelines for Planning and Implementation in District Hospitals
Nested case-control study of health workers exposed to confirmed COVID-19 patients.
Similar objectives to the cohort study but case-control studies may be cheaper and provide robust evidence to characterize and assess the risk factors for SARS-CoV-2 infection in health workers exposed to COVID-19 p...atients.
Health workers with confirmed COVID-19 will be recruited as cases and other health workers in the same health care setting without infection will be recruited as controls (incidence density sampling).
Secondary objectives are similar to the cohort study.
more
Prepared by the Independent Panel for Pandemic Preparedness and Response for the WHO Executive Board, January 2021
“The world was not as prepared as it should have been, and it must do better,” concludes a WHO panel reviewing the pandemic response "
Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
Kenya Quality Model for Health - Level 2 Facilities
This interim guidance is aimed at assisting organizers of international meetings attended by individuals from EVD-affected countries and individuals with a travel history to EVD-affected countries within the previous 3 weeks.
The first part is intended for organizers of international meetings, to ...safely plan and conduct these events. The second part is addressed to public health authorities directly involved in supporting such international meetings.
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more